Fetroja and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Fetroja (cefiderocol sulfate tosylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Meropenem, and have Pneumonia.

The study is created by eHealthMe based on reports of 190 people who have side effects when taking Fetroja from the FDA, and is updated regularly.

What is Fetroja?

Fetroja has active ingredients of cefiderocol sulfate tosylate. eHealthMe is studying from 190 Fetroja users. Check the latest studies of Fetroja.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

190 people reported to have side effects when taking Fetroja.
Among them, 43 people (22.63%) died.

Among these 43 people:

How long have people been on Fetroja when they died? *

What is the gender of people who died when taking Fetroja? *

female: 29.41 %
male: 70.59 %

What is the age of people who died when taking Fetroja? *

What are other drugs people take besides Fetroja? *

What are other side effects people have before they died? *

Infection: 4 people, 9.30%
Drug Resistance (reduction in effectiveness of a drug): 2 people, 4.65%
Erythema Multiforme (a type of hypersensitivity reaction): 1 person, 2.33%

What are the existing conditions these people have? *

Pneumonia: 15 people, 34.88%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 13 people, 30.23%
Acinetobacter Infection (infection by group of bacteria commonly found in soil and water): 12 people, 27.91%
Drug Resistance (reduction in effectiveness of a drug): 8 people, 18.60%
Stenotrophomonas Infection: 5 people, 11.63%
Klebsiella Infection: 5 people, 11.63%
Acinetobacter Test Positive: 4 people, 9.30%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 9.30%
Pathogen Resistance: 3 people, 6.98%
Multiple-Drug Resistance: 3 people, 6.98%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fetroja:

Fetroja (190 reports)

Expand to all the drugs that have ingredients of cefiderocol sulfate tosylate:

Death and drugs with ingredients of cefiderocol sulfate tosylate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fetroja:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,107 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cefiderocol sulfate tosylate (the active ingredients of Fetroja) and Fetroja (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.